Statement Responding to the March 10th Letter from the House Oversight Committee
March 10, 2016
Statement of Robert Kelner, Partner at Covington & Burling representing Valeant Pharmaceuticals:
We are surprised and puzzled by the committee’s statement given that we have produced more than 78,000 pages of documents. As is standard procedure for any company responding to a congressional investigation and engaged in litigation, we have declined to produce documents covered by the attorney-client privilege, and we are preparing a log for the committee detailing what documents are being withheld under that privilege. We have cooperated with the committee’s review from the beginning and look forward to providing them with that log, pursuant to their request.